Characterization of the intrinsic AmpC β-lactamase of Escherichia marmotae and its impact on decreased susceptibility to cefiderocol and resistance to broad-spectrum cephalosporins
Journal of Antimicrobial Chemotherapy · 04.08.2026 · 81 (9)
DOI: 10.1093/jac/dkag271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 13.08.2026. Verfasst von Samanta Freire und 5 weiteren Autor:innen. Beteiligte Einrichtung: Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland. Hauptthemen laut MEDLINE: Cephalosporins, beta-Lactamases, Anti-Bacterial Agents, Bacterial Proteins. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fribourg, Switzerland, NARA, Federal Office of Public Health, Switzerland.
Abstract (Originalsprache)
Objectives
We aimed to characterize the intrinsic AmpC β-lactamase (EMC-2) from an Escherichia marmotae clinical isolate recovered from a bloodstream infection, exhibiting resistance to broad-spectrum cephalosporins.
Methods
Cloning experiments in Escherichia coli were performed to evaluate the impact of the respective AmpC enzymes on β-lactam susceptibility. Purification of the enzymes was performed by ion-exchange chromatography, and kinetic assays were performed by UV spectrophotometry.
Results
By comparing the sequence of this AmpC with that of a WT E. marmotae, four amino acid substitutions and one amino acid deletion at position 296 were identified. Furthermore, a promoter alteration was responsible for an enhanced gene expression. Production of EMC-2 in E. coli TOP10 conferred an extended-spectrum AmpC (ESAC) phenotype characterized by increased MICs of cefotaxime, cefepime and cefiderocol. Site-directed mutagenesis confirmed the important role of the Arg296 deletion in this phenotype.
Conclusions
We showed that the intrinsic AmpC of E. marmotae can acquire both structural and regulatory modifications that broaden its substrate spectrum, leading to reduced susceptibility to clinically relevant β-lactams, including cefiderocol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- MCL, Medizinische Laboratorien, Niederwangen, Switzerland.
- Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
ORCID-Profile: Jacqueline Findlay, Patrice Nordmann, Laurent Poirel
Förderung
- University of Fribourg, Switzerland
- NARA
- Federal Office of Public Health, Switzerland
Zitieren
APA
Freire, S., Alvarez, S. M., Findlay, J., Vogel, M., Nordmann, P., & Poirel, L. (2026). Characterization of the intrinsic AmpC β-lactamase of Escherichia marmotae and its impact on decreased susceptibility to cefiderocol and resistance to broad-spectrum cephalosporins. Journal of Antimicrobial Chemotherapy, 81(9). https://doi.org/10.1093/jac/dkag271
Vancouver
Freire S, Alvarez SM, Findlay J, Vogel M, Nordmann P, Poirel L. Characterization of the intrinsic AmpC β-lactamase of Escherichia marmotae and its impact on decreased susceptibility to cefiderocol and resistance to broad-spectrum cephalosporins. Journal of Antimicrobial Chemotherapy. 2026;81(9). doi:10.1093/jac/dkag271
BibTeX
@article{Freire2026,
author = {Freire, Samanta and Alvarez, Sandra Martinez and Findlay, Jacqueline and Vogel, Miriam and Nordmann, Patrice and Poirel, Laurent},
title = {Characterization of the intrinsic AmpC β-lactamase of Escherichia marmotae and its impact on decreased susceptibility to cefiderocol and resistance to broad-spectrum cephalosporins},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {9},
doi = {10.1093/jac/dkag271}
}
EUVIMED